Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas

A. Iolascon, L. Giordani, A. Borriello, R. Carbone, A. Izzo, G. P. Tonini, C. Gambini, F. Della Ragione

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. (C) 2000 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)1171-1176
Number of pages6
JournalBritish Journal of Cancer
Volume82
Issue number6
Publication statusPublished - 2000

Fingerprint

Neuroblastoma
Transforming Growth Factor beta
Transforming Growth Factor beta1
Gene Expression
Transforming Growth Factor beta Receptors
Neoplasms
betaglycan
Genes
Reverse Transcription
Down-Regulation
Cell Proliferation
Polymerase Chain Reaction
Growth

Keywords

  • Neuroblastoma
  • TGF-β1
  • TGF-βRI
  • TGF-βRII
  • TGF-βRIII

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Iolascon, A., Giordani, L., Borriello, A., Carbone, R., Izzo, A., Tonini, G. P., ... Della Ragione, F. (2000). Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. British Journal of Cancer, 82(6), 1171-1176.

Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. / Iolascon, A.; Giordani, L.; Borriello, A.; Carbone, R.; Izzo, A.; Tonini, G. P.; Gambini, C.; Della Ragione, F.

In: British Journal of Cancer, Vol. 82, No. 6, 2000, p. 1171-1176.

Research output: Contribution to journalArticle

Iolascon, A, Giordani, L, Borriello, A, Carbone, R, Izzo, A, Tonini, GP, Gambini, C & Della Ragione, F 2000, 'Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas', British Journal of Cancer, vol. 82, no. 6, pp. 1171-1176.
Iolascon A, Giordani L, Borriello A, Carbone R, Izzo A, Tonini GP et al. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. British Journal of Cancer. 2000;82(6):1171-1176.
Iolascon, A. ; Giordani, L. ; Borriello, A. ; Carbone, R. ; Izzo, A. ; Tonini, G. P. ; Gambini, C. ; Della Ragione, F. / Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. In: British Journal of Cancer. 2000 ; Vol. 82, No. 6. pp. 1171-1176.
@article{b4d252ab79de486d989a935a98dbbe59,
title = "Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas",
abstract = "Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. (C) 2000 Cancer Research Campaign.",
keywords = "Neuroblastoma, TGF-β1, TGF-βRI, TGF-βRII, TGF-βRIII",
author = "A. Iolascon and L. Giordani and A. Borriello and R. Carbone and A. Izzo and Tonini, {G. P.} and C. Gambini and {Della Ragione}, F.",
year = "2000",
language = "English",
volume = "82",
pages = "1171--1176",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas

AU - Iolascon, A.

AU - Giordani, L.

AU - Borriello, A.

AU - Carbone, R.

AU - Izzo, A.

AU - Tonini, G. P.

AU - Gambini, C.

AU - Della Ragione, F.

PY - 2000

Y1 - 2000

N2 - Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. (C) 2000 Cancer Research Campaign.

AB - Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. (C) 2000 Cancer Research Campaign.

KW - Neuroblastoma

KW - TGF-β1

KW - TGF-βRI

KW - TGF-βRII

KW - TGF-βRIII

UR - http://www.scopus.com/inward/record.url?scp=0034010649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034010649&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 1171

EP - 1176

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -